Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
Summary Romosozumab, which binds sclerostin, rebuilds the skeletal foundation before transitioning to antiresorptive treatment. This subgroup analysis of an international, randomized, double-blind study in postmenopausal women with osteoporosis showed efficacy and safety outcomes for romosozumab fol...
Gespeichert in:
| Veröffentlicht in: | Archives of osteoporosis 2019-06, Vol.14 (1), p.59-59, Article 59 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 59 |
|---|---|
| container_issue | 1 |
| container_start_page | 59 |
| container_title | Archives of osteoporosis |
| container_volume | 14 |
| creator | Miyauchi, Akimitsu Dinavahi, Rajani V. Crittenden, Daria B. Yang, Wenjing Maddox, Judy C. Hamaya, Etsuro Nakamura, Yoichi Libanati, Cesar Grauer, Andreas Shimauchi, Junichiro |
| description | Summary
Romosozumab, which binds sclerostin, rebuilds the skeletal foundation before transitioning to antiresorptive treatment. This subgroup analysis of an international, randomized, double-blind study in postmenopausal women with osteoporosis showed efficacy and safety outcomes for romosozumab followed by denosumab in Japanese women were generally consistent with those for the overall population.
Purpose
In the international, randomized, double-blind, phase 3 FRActure study, in postmenopausal woMen with ostEoporosis (FRAME; NCT01575834), romosozumab followed by denosumab significantly improved bone mineral density (BMD) and reduced fracture risk. This report evaluates Japanese women in FRAME.
Methods
Postmenopausal women with osteoporosis (T-score − 3.5 to − 2.5 at total hip or femoral neck) received romosozumab 210 mg or placebo subcutaneously monthly for 12 months, then each group received denosumab 60 mg subcutaneously every 6 months for 24 months. The key endpoint for Japanese women was BMD change. Other endpoints included new vertebral, clinical, and nonvertebral fracture; the subgroup analysis did not have adequate power to demonstrate statistically significant reductions.
Results
Of 7180 enrolled subjects, 492 (6.9%) were Japanese (247 romosozumab, 245 placebo). BMD increases from baseline were greater (
P
|
| doi_str_mv | 10.1007/s11657-019-0608-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6551345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2245675650</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423z-6fd1bf28c95dd49a6ebe613d3191098eee094d1aed774b59f71afc3afa25fe7e3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhiMEoqXwAFyQjxwasJ3YSS5IVdXSoiIkBGfLicdbV4kdPMnC7tNw5jH6ZDhKWcGFk0ea7_9nPH-WvWT0DaO0eouMSVHllDU5lbTO94-yY1ZLnheClY8PNedH2TPEO5ogJuTT7KhIwjpJj7Nf176LoBEMaYMHMjgPUffEgEc37YgNkbD7nzvQkQRLYhgChv086PaUbJGMve6gDaeJ6_vwfXHZEb7yuAiST8AFJ86T6RbIBz1qDwgE53YTwzwu1NIY3TZMafLl57OPF2SKLtXaGwI_pmWX4J9nT6zuEV48vCfZ18uLL-dX-c2n99fnZzd5V_Jin0trWGt53TXCmLLRElqQrDAFaxhtagCgTWmYBlNVZSsaWzFtu0JbzYWFCoqT7N3qO87tAKYDP6WLqDG6QcedCtqpfzve3apN2CopBCtKkQxePxjE8G0GnNTgsIO-Tx8PMyrOSyErIQVNKFvRLgbECPYwhlG1ZKzWjFXKWC0Zq33SvPp7v4PiT6gJ4CuAqeU3ENVdmKNPN_uP628dqbj3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2245675650</pqid></control><display><type>article</type><title>Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Miyauchi, Akimitsu ; Dinavahi, Rajani V. ; Crittenden, Daria B. ; Yang, Wenjing ; Maddox, Judy C. ; Hamaya, Etsuro ; Nakamura, Yoichi ; Libanati, Cesar ; Grauer, Andreas ; Shimauchi, Junichiro</creator><creatorcontrib>Miyauchi, Akimitsu ; Dinavahi, Rajani V. ; Crittenden, Daria B. ; Yang, Wenjing ; Maddox, Judy C. ; Hamaya, Etsuro ; Nakamura, Yoichi ; Libanati, Cesar ; Grauer, Andreas ; Shimauchi, Junichiro</creatorcontrib><description>Summary
Romosozumab, which binds sclerostin, rebuilds the skeletal foundation before transitioning to antiresorptive treatment. This subgroup analysis of an international, randomized, double-blind study in postmenopausal women with osteoporosis showed efficacy and safety outcomes for romosozumab followed by denosumab in Japanese women were generally consistent with those for the overall population.
Purpose
In the international, randomized, double-blind, phase 3 FRActure study, in postmenopausal woMen with ostEoporosis (FRAME; NCT01575834), romosozumab followed by denosumab significantly improved bone mineral density (BMD) and reduced fracture risk. This report evaluates Japanese women in FRAME.
Methods
Postmenopausal women with osteoporosis (T-score − 3.5 to − 2.5 at total hip or femoral neck) received romosozumab 210 mg or placebo subcutaneously monthly for 12 months, then each group received denosumab 60 mg subcutaneously every 6 months for 24 months. The key endpoint for Japanese women was BMD change. Other endpoints included new vertebral, clinical, and nonvertebral fracture; the subgroup analysis did not have adequate power to demonstrate statistically significant reductions.
Results
Of 7180 enrolled subjects, 492 (6.9%) were Japanese (247 romosozumab, 245 placebo). BMD increases from baseline were greater (
P
< 0.001) for romosozumab-to-denosumab than placebo-to-denosumab at the lumbar spine (36 months, 12.7%), total hip (4.2%), and femoral neck (4.1%). Fracture risk was lower through 36 months for romosozumab-to-denosumab vs placebo-to-denosumab for new vertebral (1.7% vs 4.5%; relative risk reduction (RRR) 63%,
P
= 0.070), clinical (3.2% vs 7.3%; RRR 53%,
P
= 0.072), nonvertebral (2.8% vs 6.1%; RRR 50%,
P
= 0.12), and all other fracture types evaluated. Rates of adverse events and positively adjudicated serious cardiovascular events were generally balanced between groups.
Conclusions
Efficacy and safety for romosozumab-to-denosumab were similar between Japanese women and the overall population. The sequence of romosozumab to rebuild the skeletal foundation before transitioning to antiresorptive treatment with denosumab is a promising regimen for Japanese postmenopausal women with osteoporosis at high risk of fracture.</description><identifier>ISSN: 1862-3522</identifier><identifier>EISSN: 1862-3514</identifier><identifier>DOI: 10.1007/s11657-019-0608-z</identifier><identifier>PMID: 31168657</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Bone Density - drug effects ; Bone Density Conservation Agents - administration & dosage ; Denosumab - administration & dosage ; Double-Blind Method ; Endocrinology ; Female ; Femur Neck ; Fractures, Bone - epidemiology ; Fractures, Bone - prevention & control ; Humans ; Japan - epidemiology ; Lumbar Vertebrae ; Medicine ; Medicine & Public Health ; Middle Aged ; Original ; Original Article ; Orthopedics ; Osteoporosis ; Osteoporosis, Postmenopausal - drug therapy ; Risk ; Risk Reduction Behavior</subject><ispartof>Archives of osteoporosis, 2019-06, Vol.14 (1), p.59-59, Article 59</ispartof><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423z-6fd1bf28c95dd49a6ebe613d3191098eee094d1aed774b59f71afc3afa25fe7e3</citedby><cites>FETCH-LOGICAL-c423z-6fd1bf28c95dd49a6ebe613d3191098eee094d1aed774b59f71afc3afa25fe7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11657-019-0608-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11657-019-0608-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31168657$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyauchi, Akimitsu</creatorcontrib><creatorcontrib>Dinavahi, Rajani V.</creatorcontrib><creatorcontrib>Crittenden, Daria B.</creatorcontrib><creatorcontrib>Yang, Wenjing</creatorcontrib><creatorcontrib>Maddox, Judy C.</creatorcontrib><creatorcontrib>Hamaya, Etsuro</creatorcontrib><creatorcontrib>Nakamura, Yoichi</creatorcontrib><creatorcontrib>Libanati, Cesar</creatorcontrib><creatorcontrib>Grauer, Andreas</creatorcontrib><creatorcontrib>Shimauchi, Junichiro</creatorcontrib><title>Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension</title><title>Archives of osteoporosis</title><addtitle>Arch Osteoporos</addtitle><addtitle>Arch Osteoporos</addtitle><description>Summary
Romosozumab, which binds sclerostin, rebuilds the skeletal foundation before transitioning to antiresorptive treatment. This subgroup analysis of an international, randomized, double-blind study in postmenopausal women with osteoporosis showed efficacy and safety outcomes for romosozumab followed by denosumab in Japanese women were generally consistent with those for the overall population.
Purpose
In the international, randomized, double-blind, phase 3 FRActure study, in postmenopausal woMen with ostEoporosis (FRAME; NCT01575834), romosozumab followed by denosumab significantly improved bone mineral density (BMD) and reduced fracture risk. This report evaluates Japanese women in FRAME.
Methods
Postmenopausal women with osteoporosis (T-score − 3.5 to − 2.5 at total hip or femoral neck) received romosozumab 210 mg or placebo subcutaneously monthly for 12 months, then each group received denosumab 60 mg subcutaneously every 6 months for 24 months. The key endpoint for Japanese women was BMD change. Other endpoints included new vertebral, clinical, and nonvertebral fracture; the subgroup analysis did not have adequate power to demonstrate statistically significant reductions.
Results
Of 7180 enrolled subjects, 492 (6.9%) were Japanese (247 romosozumab, 245 placebo). BMD increases from baseline were greater (
P
< 0.001) for romosozumab-to-denosumab than placebo-to-denosumab at the lumbar spine (36 months, 12.7%), total hip (4.2%), and femoral neck (4.1%). Fracture risk was lower through 36 months for romosozumab-to-denosumab vs placebo-to-denosumab for new vertebral (1.7% vs 4.5%; relative risk reduction (RRR) 63%,
P
= 0.070), clinical (3.2% vs 7.3%; RRR 53%,
P
= 0.072), nonvertebral (2.8% vs 6.1%; RRR 50%,
P
= 0.12), and all other fracture types evaluated. Rates of adverse events and positively adjudicated serious cardiovascular events were generally balanced between groups.
Conclusions
Efficacy and safety for romosozumab-to-denosumab were similar between Japanese women and the overall population. The sequence of romosozumab to rebuild the skeletal foundation before transitioning to antiresorptive treatment with denosumab is a promising regimen for Japanese postmenopausal women with osteoporosis at high risk of fracture.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Denosumab - administration & dosage</subject><subject>Double-Blind Method</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Femur Neck</subject><subject>Fractures, Bone - epidemiology</subject><subject>Fractures, Bone - prevention & control</subject><subject>Humans</subject><subject>Japan - epidemiology</subject><subject>Lumbar Vertebrae</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Osteoporosis</subject><subject>Osteoporosis, Postmenopausal - drug therapy</subject><subject>Risk</subject><subject>Risk Reduction Behavior</subject><issn>1862-3522</issn><issn>1862-3514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhiMEoqXwAFyQjxwasJ3YSS5IVdXSoiIkBGfLicdbV4kdPMnC7tNw5jH6ZDhKWcGFk0ea7_9nPH-WvWT0DaO0eouMSVHllDU5lbTO94-yY1ZLnheClY8PNedH2TPEO5ogJuTT7KhIwjpJj7Nf176LoBEMaYMHMjgPUffEgEc37YgNkbD7nzvQkQRLYhgChv086PaUbJGMve6gDaeJ6_vwfXHZEb7yuAiST8AFJ86T6RbIBz1qDwgE53YTwzwu1NIY3TZMafLl57OPF2SKLtXaGwI_pmWX4J9nT6zuEV48vCfZ18uLL-dX-c2n99fnZzd5V_Jin0trWGt53TXCmLLRElqQrDAFaxhtagCgTWmYBlNVZSsaWzFtu0JbzYWFCoqT7N3qO87tAKYDP6WLqDG6QcedCtqpfzve3apN2CopBCtKkQxePxjE8G0GnNTgsIO-Tx8PMyrOSyErIQVNKFvRLgbECPYwhlG1ZKzWjFXKWC0Zq33SvPp7v4PiT6gJ4CuAqeU3ENVdmKNPN_uP628dqbj3</recordid><startdate>20190605</startdate><enddate>20190605</enddate><creator>Miyauchi, Akimitsu</creator><creator>Dinavahi, Rajani V.</creator><creator>Crittenden, Daria B.</creator><creator>Yang, Wenjing</creator><creator>Maddox, Judy C.</creator><creator>Hamaya, Etsuro</creator><creator>Nakamura, Yoichi</creator><creator>Libanati, Cesar</creator><creator>Grauer, Andreas</creator><creator>Shimauchi, Junichiro</creator><general>Springer London</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190605</creationdate><title>Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension</title><author>Miyauchi, Akimitsu ; Dinavahi, Rajani V. ; Crittenden, Daria B. ; Yang, Wenjing ; Maddox, Judy C. ; Hamaya, Etsuro ; Nakamura, Yoichi ; Libanati, Cesar ; Grauer, Andreas ; Shimauchi, Junichiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423z-6fd1bf28c95dd49a6ebe613d3191098eee094d1aed774b59f71afc3afa25fe7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Denosumab - administration & dosage</topic><topic>Double-Blind Method</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Femur Neck</topic><topic>Fractures, Bone - epidemiology</topic><topic>Fractures, Bone - prevention & control</topic><topic>Humans</topic><topic>Japan - epidemiology</topic><topic>Lumbar Vertebrae</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Osteoporosis</topic><topic>Osteoporosis, Postmenopausal - drug therapy</topic><topic>Risk</topic><topic>Risk Reduction Behavior</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyauchi, Akimitsu</creatorcontrib><creatorcontrib>Dinavahi, Rajani V.</creatorcontrib><creatorcontrib>Crittenden, Daria B.</creatorcontrib><creatorcontrib>Yang, Wenjing</creatorcontrib><creatorcontrib>Maddox, Judy C.</creatorcontrib><creatorcontrib>Hamaya, Etsuro</creatorcontrib><creatorcontrib>Nakamura, Yoichi</creatorcontrib><creatorcontrib>Libanati, Cesar</creatorcontrib><creatorcontrib>Grauer, Andreas</creatorcontrib><creatorcontrib>Shimauchi, Junichiro</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Archives of osteoporosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyauchi, Akimitsu</au><au>Dinavahi, Rajani V.</au><au>Crittenden, Daria B.</au><au>Yang, Wenjing</au><au>Maddox, Judy C.</au><au>Hamaya, Etsuro</au><au>Nakamura, Yoichi</au><au>Libanati, Cesar</au><au>Grauer, Andreas</au><au>Shimauchi, Junichiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension</atitle><jtitle>Archives of osteoporosis</jtitle><stitle>Arch Osteoporos</stitle><addtitle>Arch Osteoporos</addtitle><date>2019-06-05</date><risdate>2019</risdate><volume>14</volume><issue>1</issue><spage>59</spage><epage>59</epage><pages>59-59</pages><artnum>59</artnum><issn>1862-3522</issn><eissn>1862-3514</eissn><abstract>Summary
Romosozumab, which binds sclerostin, rebuilds the skeletal foundation before transitioning to antiresorptive treatment. This subgroup analysis of an international, randomized, double-blind study in postmenopausal women with osteoporosis showed efficacy and safety outcomes for romosozumab followed by denosumab in Japanese women were generally consistent with those for the overall population.
Purpose
In the international, randomized, double-blind, phase 3 FRActure study, in postmenopausal woMen with ostEoporosis (FRAME; NCT01575834), romosozumab followed by denosumab significantly improved bone mineral density (BMD) and reduced fracture risk. This report evaluates Japanese women in FRAME.
Methods
Postmenopausal women with osteoporosis (T-score − 3.5 to − 2.5 at total hip or femoral neck) received romosozumab 210 mg or placebo subcutaneously monthly for 12 months, then each group received denosumab 60 mg subcutaneously every 6 months for 24 months. The key endpoint for Japanese women was BMD change. Other endpoints included new vertebral, clinical, and nonvertebral fracture; the subgroup analysis did not have adequate power to demonstrate statistically significant reductions.
Results
Of 7180 enrolled subjects, 492 (6.9%) were Japanese (247 romosozumab, 245 placebo). BMD increases from baseline were greater (
P
< 0.001) for romosozumab-to-denosumab than placebo-to-denosumab at the lumbar spine (36 months, 12.7%), total hip (4.2%), and femoral neck (4.1%). Fracture risk was lower through 36 months for romosozumab-to-denosumab vs placebo-to-denosumab for new vertebral (1.7% vs 4.5%; relative risk reduction (RRR) 63%,
P
= 0.070), clinical (3.2% vs 7.3%; RRR 53%,
P
= 0.072), nonvertebral (2.8% vs 6.1%; RRR 50%,
P
= 0.12), and all other fracture types evaluated. Rates of adverse events and positively adjudicated serious cardiovascular events were generally balanced between groups.
Conclusions
Efficacy and safety for romosozumab-to-denosumab were similar between Japanese women and the overall population. The sequence of romosozumab to rebuild the skeletal foundation before transitioning to antiresorptive treatment with denosumab is a promising regimen for Japanese postmenopausal women with osteoporosis at high risk of fracture.</abstract><cop>London</cop><pub>Springer London</pub><pmid>31168657</pmid><doi>10.1007/s11657-019-0608-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1862-3522 |
| ispartof | Archives of osteoporosis, 2019-06, Vol.14 (1), p.59-59, Article 59 |
| issn | 1862-3522 1862-3514 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6551345 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Denosumab - administration & dosage Double-Blind Method Endocrinology Female Femur Neck Fractures, Bone - epidemiology Fractures, Bone - prevention & control Humans Japan - epidemiology Lumbar Vertebrae Medicine Medicine & Public Health Middle Aged Original Original Article Orthopedics Osteoporosis Osteoporosis, Postmenopausal - drug therapy Risk Risk Reduction Behavior |
| title | Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A04%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20bone%20mineral%20density%20for%201%C2%A0year%20of%20romosozumab,%20vs%20placebo,%20followed%20by%202%C2%A0years%20of%20denosumab%20in%20the%20Japanese%20subgroup%20of%20the%20pivotal%20FRAME%20trial%20and%20extension&rft.jtitle=Archives%20of%20osteoporosis&rft.au=Miyauchi,%20Akimitsu&rft.date=2019-06-05&rft.volume=14&rft.issue=1&rft.spage=59&rft.epage=59&rft.pages=59-59&rft.artnum=59&rft.issn=1862-3522&rft.eissn=1862-3514&rft_id=info:doi/10.1007/s11657-019-0608-z&rft_dat=%3Cproquest_pubme%3E2245675650%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2245675650&rft_id=info:pmid/31168657&rfr_iscdi=true |